American Association for Cancer Research

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Retrieved on: 
Monday, November 6, 2023
Avalon, Modified vaccinia Ankara, Autoimmunity, American Association for Cancer Research, Hepatology, Vaccine, Liver, Immunogenicity, LDN, PD-1, University, CHB, Research, Barinthus, Immune system, COVID-19, Efficacy, MVA, Hepatitis, Repeat, Hepatitis B, Infection, Cancer, HBsAg, Patient, Asian Liver Center, HBV, AASLD, Pharmaceutical industry, Oxford–AstraZeneca COVID-19 vaccine, Safety

The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines. The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023. As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com.

Key Points: 
  • The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.
  • The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023.
  • As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com .
  • “Today the company is focused on the development of novel T cell immunotherapeutic candidates, which evolved out of that initial vaccine research.

Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

Retrieved on: 
Monday, November 6, 2023
Ovarian cancer, Research, PARP, AACR, Acute myeloid leukemia, Therapy, USC, G&A, Conference, WEE1, Maintenance, R, Clinical Ovarian Cancer & Other Gynecologic Malignancies, National Center for Advancing Translational Sciences, Senior, Development, Uterine serous carcinoma, Biology, Partnership, Cancer, GSK, Medication, ORR, Platinum, Culture, NDA, Genentech, Safety, Amyloidosis, American Association for Cancer Research, Patient, Administration, SAN, State Administrative Expenses, Pharmaceutical industry

“Azenosertib continues to show very encouraging monotherapy anti-tumor activity, safety and tolerability in both ovarian cancer and uterine serous carcinoma.

Key Points: 
  • “Azenosertib continues to show very encouraging monotherapy anti-tumor activity, safety and tolerability in both ovarian cancer and uterine serous carcinoma.
  • Zentalis is the only company known to have both a WEE1 inhibitor, azenosertib, and a BCL-2 inhibitor, ZN-d5, in clinical development.
  • Research and Development Expenses: Research and development (R&D) expenses for the quarter ended September 30, 2023 were $46.8 million, compared to $42.2 million for the quarter ended September 30, 2022.
  • General and Administrative Expenses: General and administrative (G&A) expenses for the quarter ended September 30, 2023 were $16.0 million, compared to $12.0 million during the quarter ended September 30, 2022.

SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, November 2, 2023
Bispecific monoclonal antibody, Cycle, Patient, NRAS, FDA, Molecular Cancer Research, Research, Research and development, New Drug Application, IND, American Association for Cancer Research, CD3, PDUFA, Multiple myeloma, Amgen, TEAD, Biotechnology, Regeneron Pharmaceuticals, MAPK, Prescription Drug User Fee Act, Plantar fibromatosis, G&A, European Medicines Agency, Panitumumab, R, RAF, Solar cycle 10, MEK, Growth, Common, Annual general meeting, EMA, Solar cycle 2, NDA, Cancer, Therapy, Solar cycle 24, BCMA, Administration, BeiGene, EGFR, Pharmaceutical industry, Medical imaging

STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported third quarter financial results for the period ended September 30, 2023 and provided an update on recent business highlights.

Key Points: 
  • – PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for November 27, 2023 –
    STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported third quarter financial results for the period ended September 30, 2023 and provided an update on recent business highlights.
  • SpringWorks expects to file a Marketing Authorisation Application for nirogacestat with the European Medicines Agency (EMA) in the first half of 2024.
  • SpringWorks plans to file an IND for SW-682, the Company's TEAD inhibitor development candidate, in the fourth quarter of 2023.
  • Net Loss Attributable to Common Stockholders: SpringWorks reported a net loss of $79.4 million, or $1.27 per share, for the third quarter of 2023.

Bayer and Broad Institute of MIT and Harvard Extend Research Collaboration to Develop New Cancer Therapies

Retrieved on: 
Thursday, November 2, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, MIT, AACR, ESMO, Innovation Center station, HER2, European Society for Medical Oncology, Broad Institute, BRIC, American Society of Clinical Oncology, Harvard University, Society, Drug development, Drug discovery, Broad, Cancer, Drug resistance, American Association for Cancer Research, Patient, ASCO, EGFR, Pharmaceutical industry, Bayer, Kendall Square

Bayer and the Broad Institute of MIT and Harvard today announced that they have extended their research collaboration of 10 years by an additional five years, to develop and advance innovative cancer treatments.

Key Points: 
  • Bayer and the Broad Institute of MIT and Harvard today announced that they have extended their research collaboration of 10 years by an additional five years, to develop and advance innovative cancer treatments.
  • “Bayer’s established collaboration with the Broad Institute has already resulted in three clinical oncology candidates.
  • Bayer with its Bayer Research & Innovation Center (BRIC) is closely located to the Broad Institute in Kendall Square, Cambridge, MA.
  • BRIC houses a center of precision oncology research equipped with state-of-the-art laboratories for the development of targeted next-generation cancer therapies for patients.

Syncromune® Inc. Expands Scientific Advisory Board with Addition of Prominent Oncology Trailblazer James Armitage, M.D.

Retrieved on: 
Tuesday, October 31, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Association of American Physicians, Faculty, American College, ASCO, Dean, MD Anderson Cancer Center, Vice, Clinical professor, Hematology, American Society of Clinical Oncology, Advisory board, University of Nebraska Medical Center, Department of Medicine – University of Pamplona, Clinical Oncology, Society, Internal medicine, UNMC, College, Membership of the Royal College of Physicians of Ireland, Royal college, Nebraska Medicine, Division, Richard, University, American College of Physicians, Mayo Clinic, Cancer, Patient, American Association for Cancer Research, Transplant, Book, Coronavirus Scientific Advisory Board, Pharmaceutical industry, Nursing, Medical device, Physician

Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.

Key Points: 
  • Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.
  • Dr. Armitage has served as President of both the American Society for Transplantation and Cellular Therapy (ASTCT) and the American Society of Clinical Oncology (ASCO).
  • “We are deeply honored to have Dr. Armitage join Syncromune’s Scientific Advisory Board as chair,” stated Eamonn Hobbs, President and CEO of Syncromune.
  • He has authored or co-authored more than 600 articles and 100 book chapters and is the editor/co-editor of 27 books.

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Retrieved on: 
Thursday, October 26, 2023
Survival, COH, FDA, Birmingham School of Law, GBM, AACR, IND, Translation, DSM-IV codes, Food, UAB, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, City, Cancer, Mustang, University, Tumor microenvironment, Safety, American Association for Cancer Research, Patient, Glioblastoma, Pharmaceutical industry

WORCHESTER, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted the Company’s Investigational New Drug (“IND”) application of MB-109 for the treatment of recurrent glioblastoma (“GBM”) and high-grade astrocytoma. Mustang is planning to initiate a Phase 1 multicenter clinical trial at City of Hope (“COH”) and the University of Alabama at Birmingham (“UAB”) to assess the safety, tolerability and efficacy of MB-109, a novel combination of MB-101 (COH-developed IL13Rα2‐targeted CAR-T cell therapy) and MB-108 [Nationwide Children’s Hospital- (“Nationwide”) developed HSV-1 oncolytic virus] in adult patients with recurrent GBM and high-grade astrocytomas that express IL13Rα2 on the surface of the tumor cells.

Key Points: 
  • As previously reported, preclinical data presented at the American Association for Cancer Research (“AACR”) Annual Meeting in 2022 supported this combination therapy to potentially optimize results to treat recurrent GBM.
  • The combination leverages MB-108 to reshape the tumor microenvironment (“TME”) and make cold tumors “hot,” thereby potentially improving the efficacy of MB-101 CAR-T cell therapy.
  • Data presented separately on MB-101 and MB-108 showed that administration of these therapies was well tolerated in recurrent GBM patients.
  • Recurrent GBM remains a major challenge to treat, with a median overall survival rate of 6 months.

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Retrieved on: 
Monday, October 23, 2023
AACR, RAS, Breast, MAPK, Prevalence, Conference, NF1, KRAS, University of Louisville School of Medicine, RAL, DAB2IP, Cancer, Partnership, Breast cancer, University, Downregulation and upregulation, Therapy, American Association for Cancer Research, Pharmaceutical industry

CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces a poster presentation on the Company’s Pan-RAS platform at the American Association for Cancer Research (AACR) Special Conference in Breast Cancer Research, held October 19th to 22nd at the Westin San Diego Bayview.

Key Points: 
  • “The RAS pathway continues to be an area of immense interest within the scientific community and biopharmaceutical industry.
  • Due to the prevalence and severity of RAS-driven tumors, there is a high unmet need to discover and develop more broadly acting RAS-targeted compounds.
  • These effects are particularly common in Luminal B breast cancer.
  • As a result, we have developed a series of novel direct Pan-RAS inhibitors that exhibit a distinct binding mechanism to other currently described RAS inhibitors.

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Retrieved on: 
Thursday, October 19, 2023
Pharmacology, AACR, Mantle cell lymphoma, Data, CD1, European, Biology, MCL, Cancer, Therapy, BTK, American Association for Cancer Research, Patient, Cyclin D1, Pharmaceutical industry

NEWTOWN, Pa., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that one of the Company’s scientific collaborators, Gaël Roué, Ph.D., from the Josep Carreras Leukaemia Research Institute, Spain, made a podium presentation during the European MCL Network Annual Meeting in Dublin, Ireland on October 7, 2023 regarding promising ongoing preclinical studies of narazaciclib, in combination with ibrutinib and other targeted therapies used in the treatment for mantle cell lymphoma.

Key Points: 
  • The biology of MCL is very interesting to Onconova because of the link to cyclin D1 (CD1) overexpression.
  • We believe this molecular feature could make MCL amenable to treatment combinations that include narazaciclib,” said Steven Fruchtman, M.D., President and CEO of Onconova.
  • Together, these data provide a foundation of support for using narazaciclib in MCL and other cyclin-dependent indications.
  • Data from the combination of narazaciclib and ibrutinib showed significant synergistic anti-tumor activity in both sensitive and ibrutinib-resistant MCL models.

LEADING RESEARCH INSTITUTES TO PRESENT NEW DATA USING LUNAPHORE'S COMET™ TECHNOLOGY AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 38th ANNUAL MEETING

Retrieved on: 
Wednesday, October 25, 2023
Massachusetts General Hospital, Society for Immunotherapy of Cancer, Swiss Institute for Experimental Cancer Research, ACD, Harvard Medical School, IMCB, Max Planck Institute of Molecular Cell Biology and Genetics, Biomarker, Bio-Techne, Head, Lymphoma, HNSCC, American Association for Cancer Research, Immunotherapy, SITC, Antibody, Partnership, Titan Mare Explorer, Annual general meeting, Agency for Science, Technology and Research, Tumor microenvironment, Society, TME, Pharmaceutical industry, Research, Science

The recent studies will demonstrate the unmatched spatial biology capabilities of the company's universal, end-to-end COMET™ product suite , addressing complex biological questions from various research areas.

Key Points: 
  • The recent studies will demonstrate the unmatched spatial biology capabilities of the company's universal, end-to-end COMET™ product suite , addressing complex biological questions from various research areas.
  • Lunaphore's sponsored symposia will provide novel insights into the optimization of innovative anti-cancer therapy approaches for head and neck squamous cell carcinoma (HNSCC).
  • The presentation will discuss strategies for rapid hyperplex sequential immunofluorescence (seqIF™) panel development and optimization, as well as methodologies for high-throughput data analytics.
  • The novel seqIF™ method allows an unprecedented analysis of the immune compartment and potentially increases the clinical success of such therapies.

The Robert A. Winn Diversity in Clinical Trials Award Announces Third Group of Physicians in Program to Increase Diversity in Clinical Trials

Retrieved on: 
Wednesday, October 18, 2023
Other Philanthropy, Biotechnology, Pharmaceutical, Health, FDA, Philanthropy, Clinical Trials, Foundation, Faculty, Bristol Myers Squibb, AACR, RISE, Education, Food, Physician, Implementation, American Heart Association, VCU, Organization, Research, Gilead Sciences, Mentorship, Winn, CIPP, Interest, Curriculum, CDA, CILA, Clinical trial, Health equity, Geographic Locator Codes, VCU Massey Cancer Center, HC, ESI, Virginia Commonwealth University, Woman, The Ride to Conquer Cancer, Movement, American Association for Cancer Research, Patient, Cardiovascular disease, Food and Drug Administration Amendments Act of 2007, Pharmaceutical industry, Nursing, Oncology, Amgen

The 65 physicians selected by an independent national review committee represent healthcare institutions in 20 states across the U.S. and Puerto Rico. These Winn CDA Scholars -- 40 women and 25 men -- represent a diverse cross-section of races, ethnicities and geographic locations. They are each committed to increasing diversity in clinical trials, and bring a widely varied perspective to the program, practicing in the therapeutic areas of cancer (hematologic or solid tumors), immunologic disorders and cardiovascular diseases.

Key Points: 
  • The broader Robert A. Winn Diversity in Clinical Trials Award Program (Winn Award Program) aims to train, develop and mentor more than 308 clinical trialists and 308 medical students by 2027 who are diverse or who have a demonstrated commitment to clinical trial diversity.
  • The third cohort of physicians joins the 114 early-stage investigator physicians who have so far been trained in the Winn CDA, one of four awards offered by the Robert A. Winn Diversity in Clinical Trials Award Program.
  • “Many of our most impactful medical advances are predicated on clinical trials,” said Robert A. Winn, M.D., director and Lipman Chair in Oncology, VCU Massey Comprehensive Cancer Center and chair of the Winn Award Program National Advisory Committee.
  • The Winn Award Program encourages others in the healthcare industry to consider participating as faculty and/or sponsors.